• Caris Life Sciences Launches Whole Transcriptome Sequencing (WTS) with Novel MI Transcriptome™

    New test provides most comprehensive tumor RNA analysis in the industry, including rare fusion detection IRVING, Texas, February 5, 2019 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the launch of its newest addition to its comprehensive genomic profiling offering, MI Transcriptome™, which … Read More

  • Caris Life Sciences Names Chief Communications Officer

    IRVING, Texas, January 21, 2019 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced that Srikant (Sri) Ramaswami, has joined the company as Vice President and Chief Communications Officer. Ramaswami brings to Caris more than two decades of healthcare communications experience, and has held … Read More

  • Caris Life Sciences Raises $150 Million in Growth Capital from TPG Sixth Street Partners

    Caris to accelerate development of Next Generation Profiling to analyze whole exome, whole transcriptome and the complete cancer proteome using its proprietary artificial intelligence (AI) analytic engine, DEAN, on tens of thousands of patients with mature clinical outcomes Caris is engaged in some of the most important translational research using the proprietary ADAPT Biotargeting System … Read More

  • HonorHealth Research Institute Joins the Precision Oncology Alliance

    Powered by Caris Life Sciences, the POA advances and broadens patient access to precision medicine through comprehensive tumor profiling IRVING, Texas, Sept. 13, 2018 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced that the HonorHealth Research Institute has joined Caris’ Precision Oncology Alliance™ … Read More

  • Caris Life Sciences Selected to Perform Genomic Profiling for Hoosier Cancer Research Network Bladder Cancer Study

    IRVING, Texas, August 28, 2018 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced that the company has been selected by the Hoosier Cancer Research Network and the study’s sponsor investigator, Dr. Matthew Galsky, to perform genomic tumor profiling for a new Phase II … Read More